Compare Main Street Capital Corporation (MAIN) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Main Street Capital Corporation vs TG Therapeutics Inc — how do they compare? Main Street Capital Corporation trades at $58.73 (market cap $5.52B), while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: TG Therapeutics Inc is the larger of the two by market cap, and Main Street Capital Corporation pays a 5.39% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| MAIN | TGTX | |
|---|---|---|
Market Cap | $5.52B | $7.64B |
Sector | Financials | Health |
52-Week High | $67.54 | $59.06 |
52-Week Low | $49.63 | $26.94 |
Dividend Yield | 5.39% | — |
Enterprise Value | — | $7.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Main Street Capital (MAIN) trades at $58.51, slightly below the consensus price target of $56.67, with mixed technical signals showing bullish moving averages but overbought RSI levels. The company maintains strong profitability with an 80.77% net income margin and 14.92% ROE, though Q2 2026 earnings of $0.97 per share missed expectations. Recent dividend announcements and portfolio appreciation highlight MAIN's income-focused strategy in the BDC sector.
MAIN presents a stable income opportunity with consistent dividends, but faces headwinds from higher expenses impacting recent earnings. The stock's current valuation at 11.85x P/E appears reasonable, though investor caution is warranted given the majority hold rating from analysts and competitive pressures in the private credit market.
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Main Street Capital Corporation
Main Street Capital Corp is an investment firm engaged in providing customized debt and equity financing to lower middle market companies and debt capital to middle market companies. The investment portfolio of the company is typically made to support management buyouts, recapitalizations, growth financings, refinancings and acquisitions of companies that operate in diverse industry sectors. The group invests in secured debt investments, equity investments, warrants and other securities of the lower middle market and middle market companies based in the US. Business is functioned through the U.S region and it derives the majority of the income from the source of fee, commission, and interest.
Read more on MAIN →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
